Crestone, Inc
Crestone is a Boulder, Colorado based clinical stage biopharmaceutical company dedicated to developing novel drugs with entirely new mechanisms to treat serious bacterial infections, including C. difficile, antibiotic-resistant Gram-positive infections, tuberculosis, and more. The company focuses on inventing and researching small molecule drugs to combat antimicrobial resistance and improve public health.
Industries
Nr. of Employees
small (1-50)
Crestone, Inc
6075 Longbow Dr Suite 130, Boulder, CO 80301
Patents
Substituted phenylether-thienopyridone compounds with antibacterial activity
US-8697720-B2
View Details
Substituted phenylether-thienopyridone compounds with antibacterial activity
US-8697720-B2
View DetailsProducts
MetRS-targeting small-molecule for C. difficile (clinical-stage)
A narrow-spectrum oral small-molecule protein synthesis inhibitor that targets methionyl-tRNA synthetase to treat Clostridioides difficile infection; developed to minimize disruption of normal intestinal microbiota and to reduce toxin production and sporulation.
Gram-positive antibacterial candidate evaluated in hollow-fiber model
A small-molecule antibacterial candidate advanced through hollow-fiber system modeling to assess efficacy against Gram-positive pathogens in preclinical pharmacodynamic studies.
Benzothiazole-amide MmpL3 inhibitor for NTM/TB (preclinical)
A preclinical anti-mycobacterial program focused on benzothiazole-amide compounds that inhibit the MmpL3 protein essential for mycobacterial cell-wall synthesis, showing potency against nontuberculous mycobacteria and multidrug-resistant strains.
MetRS-targeting small-molecule for C. difficile (clinical-stage)
A narrow-spectrum oral small-molecule protein synthesis inhibitor that targets methionyl-tRNA synthetase to treat Clostridioides difficile infection; developed to minimize disruption of normal intestinal microbiota and to reduce toxin production and sporulation.
Gram-positive antibacterial candidate evaluated in hollow-fiber model
A small-molecule antibacterial candidate advanced through hollow-fiber system modeling to assess efficacy against Gram-positive pathogens in preclinical pharmacodynamic studies.
Benzothiazole-amide MmpL3 inhibitor for NTM/TB (preclinical)
A preclinical anti-mycobacterial program focused on benzothiazole-amide compounds that inhibit the MmpL3 protein essential for mycobacterial cell-wall synthesis, showing potency against nontuberculous mycobacteria and multidrug-resistant strains.
Services
Sponsorship and coordination of Phase 1–2 multicenter clinical studies including site selection, enrollment, and data collection for infectious-disease drug candidates.
Sponsorship and coordination of Phase 1–2 multicenter clinical studies including site selection, enrollment, and data collection for infectious-disease drug candidates.
Expertise Areas
- Clinical trial management
- Small-molecule antibacterial discovery
- Antimicrobial resistance research
- Medicinal and process chemistry
Key Technologies
- Targeted small-molecule inhibitors of methionyl-tRNA synthetase
- MmpL3-targeting anti-mycobacterial compounds
- Hollow-fiber infection model
- In vivo pharmacodynamic models
News & Updates
Crestone is proud to be a sponsor of the Peggy Lillis Foundation FIGHT C. DIFF. Gala in Brooklyn, NY on October 28, 2022.
Crestone presented a poster on Phase 2 Clinical Trial Design for CRS3123, a novel treatment for C. difficile infections, at the Keystone Symposia on antimicrobial resistance and microbiome.
Crestone delivered an oral presentation on broad-spectrum antivirals at the World Antiviral Conference 2022.
Crestone presented a poster on addressing the antimicrobial resistance challenge at the WAMR Conference 2022.
Crestone presented on in vivo pharmacodynamic evaluation of CRS0540 at the ASM Microbe conference.
Crestone presented on NTM poster presentations at the Colorado Mycobacteria Conference 2022.
Crestone is proud to be a sponsor of the Peggy Lillis Foundation FIGHT C. DIFF. Gala in Brooklyn, NY on October 28, 2022.
Crestone presented a poster on Phase 2 Clinical Trial Design for CRS3123, a novel treatment for C. difficile infections, at the Keystone Symposia on antimicrobial resistance and microbiome.
Crestone delivered an oral presentation on broad-spectrum antivirals at the World Antiviral Conference 2022.
Crestone presented a poster on addressing the antimicrobial resistance challenge at the WAMR Conference 2022.
Crestone presented on in vivo pharmacodynamic evaluation of CRS0540 at the ASM Microbe conference.
Crestone presented on NTM poster presentations at the Colorado Mycobacteria Conference 2022.